DUBLIN--(BUSINESS WIRE)--The "Cancer Biomarkers Market by Type, Cancer Type, Profiling Technology, Application - Global Forecast to 2022" report has been added to ResearchAndMarkets.com's offering.
The global cancer biomarkers market is projected to reach USD 20.48 Billion by 2022 from USD 11.53 Billion in 2017, at a CAGR of 12.2%.
The cancer biomarkers market on the basis of cancer type is classified into breast, lung, colorectal, prostate, melanoma, leukemia, thyroid, bladder, non-hodgkin's lymphoma, kidney, and other cancers. In 2017, the breast cancer segment is expected to account for the largest share of the global market by cancer type.
On the basis of biomarker type, the cancer biomarkers market segmented into protein biomarker, genetic biomarker, and other biomarkers. In 2017, the protein biomarkers segment is expected to account for the largest share of the global market for cancer biomarkers.
On the basis of application, the cancer biomarkers market is classified into diagnostics, research and development, prognostics, risk assessment, and other applications. In 2017, the diagnostics segment is expected to account for largest share of the global market for cancer biomarkers.
The cancer biomarkers market on the basis of profiling technology is classified into omics technology, imaging technology, immunoassay, bioinformatics, and cytogenetics. The omics technologies segment is expected to account for the largest share of the global market for cancer biomarkers in 2017.
Market Dynamics
Drivers
- Technological Advancements
- Rising Incidence of Cancer
- Increasing Use of Cancer Biomarkers in Drug Discovery & Development
- Increasing Research on Cancer Biomarkers
Restraints
- Unfavorable Regulatory and Reimbursement Scenario
- High Capital Investment and Low Benefit-Cost Ratio
- Technical Issues Related to Sample Collection and Storage
Opportunities
- Personalized Medicine
- Companion Diagnostics
- Emerging Economies
Challenges
- Proving the Clinical Validity and Utility of Biomarker-Based Tests
Key Topics Covered
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Cancer Biomarkers Market, By Biomarker Type
7 Cancer Biomarker Market, By Cancer Type
8 Cancer Biomarkers Market, By Profiling Technology
9 Cancer Biomarkers Market, By Application
10 Cancer Biomarkers Market, By Region
11 Competitive Landscape
12 Company Profiles
- Abbott Laboratories
- Agilent Technologies
- Becton, Dickinson and Company
- Bio-Rad Laboratories
- Biomrieux SA
- Danaher Corporation
- GE Healthcare
- Hologic
- Illumina
- Merck & Co.
- Myriad Genetics
- Qiagen N.V.
- Quest Diagnostics
- Roche Diagnostics
- Sysmex Corporation
- Thermo Fisher Scientific
For more information about this report visit https://www.researchandmarkets.com/research/582zd3/worldwide_cancer?w=4
